Sector
PharmaceuticalsOpen
₹38.79Prev. Close
₹38.06Turnover(Lac.)
₹4.01Day's High
₹38.79Day's Low
₹37.552 Week's High
₹56.952 Week's Low
₹31.2Book Value
₹41.55Face Value
₹10Mkt Cap (₹ Cr.)
69.91P/E
9.23EPS
4.12Divi. Yield
0Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 14.9 | 14.9 | 14.95 | 14.85 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 39.49 | 36.97 | 32.19 | 27.7 |
Net Worth | 54.39 | 51.87 | 47.14 | 42.55 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2020 | Mar-2018 | Mar-2017 | Mar-2016 |
---|---|---|---|---|
Revenue | 55.35 | 47 | 34.12 | 28.58 |
yoy growth (%) | 17.76 | 37.72 | 19.39 | 60.68 |
Raw materials | -8.55 | -9.56 | -8.14 | -8.79 |
As % of sales | 15.45 | 20.35 | 23.86 | 30.78 |
Employee costs | -9.99 | -7.58 | -5.49 | -4.34 |
Y/e 31 Mar( In .Cr) | Mar-2020 | Mar-2018 | Mar-2017 | Mar-2016 |
---|---|---|---|---|
Profit before tax | 4.25 | 4 | 2.83 | 0.78 |
Depreciation | -5.17 | -4.63 | -3.9 | -3.35 |
Tax paid | 0.18 | -0.88 | -0.33 | 0.12 |
Working capital | 8.28 | 4.54 | 4.71 | 8.12 |
Other operating items |
Y/e 31 Mar | Mar-2020 | Mar-2018 | Mar-2017 | Mar-2016 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 17.76 | 37.72 | 19.39 | 60.68 |
Op profit growth | 14.62 | 42.61 | 105.79 | 32.15 |
EBIT growth | 15.34 | 54.58 | 230.95 | 76.34 |
Net profit growth | 42.28 | 24.72 | 175.16 | 96.62 |
Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|---|
Gross Sales | 46.67 | 45.45 | 52.23 | 51.39 | 51.78 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 46.67 | 45.45 | 52.23 | 51.39 | 51.78 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 4.8 | 0.04 | 0.04 | 0.1 | 0.08 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,687 | 94.51 | 4,04,767.81 | 2,000.46 | 0.95 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,722.75 | 80.79 | 1,78,467.89 | 667 | 0.45 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,502.1 | 24.63 | 1,21,323.17 | 1,485.4 | 1.07 | 4,254.47 | 397.42 |
Dr Reddys Laboratories Ltd DRREDDY | 1,363.15 | 21.27 | 1,13,756.67 | 1,200.7 | 0.59 | 5,546.3 | 345.79 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,260.35 | 57.91 | 1,10,340.1 | 474 | 0.98 | 2,385 | 224.33 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Whole-time Director
Kalyan Ram Mangipudi
Whole-time Director
Alangudi Sankaranarayanan
Independent Director
Kunda Kalpana
Non Executive Director
Karopadi Shivanand Nayak
Whole Time Director & CFO
K Sri Kalyan
Independent Director
Shyam Sunder Tipparaju
Company Sec. & Compli. Officer
A V Kiran
Additional Director
Satyanarayan Vedula
Survey #349/A Pregnapur Vlge,
Telangana - 502311
Tel: -
Website: http://www.vivobio.com
Email: investors@vivobio.com
1-2-285,
Domalguda, J B Apartments,
Hyderabad - 500 029
Tel: 91-40-27642217 /2763
Website: www.aarthiconsultants.com
Email: info@aarthiconsultants.com
Summary
Vivo Bio Tech Limited, established in February, 1987 is a full service CRO offering drug development & discovery services to pharmaceutical & biotech companies world-wide in accordance with OECD, AAAL...
Read More
Reports by Vivo Bio Tech Ltd
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.